# Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

Source: https://onco.cc/trials/nct06601504/  
OnCo record `nct06601504` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Rituximab, Gemcitabine in diffuse large b-cell lymphoma, run by Hutchmed, active and no longer recruiting.

## Summary

Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL is a phase 2 interventional study registered as NCT06601504 by Hutchmed, with 61 participants enrolled, started 2024-11-05 and due to reach its primary completion in 2026-05-12. Interventions recorded: HMPL-760 planned dose 1, R-GemOx, HMPL-760 placebo planned dose 1, HMPL-760 planned dose 2, HMPL-760 placebo planned dose 2. Conditions listed: Relapsed/Refractory Diffuse Large B-Cell Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06601504
- Phase: 2
- Setting: A Phase II Randomized, Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma(R/R DLBCL)
- Sponsor: Hutchmed
- Enrolled: 61

## Sources

- ClinicalTrials.gov NCT06601504: https://clinicaltrials.gov/study/NCT06601504

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Rituximab](https://onco.cc/drugs/rituximab/)
- companies: [Hutchmed](https://onco.cc/companies/hutchmed/)

---
JSON: https://onco.cc/api/v1/entities/nct06601504.json